Catalyst overview
Research summary
This catalyst tracks a Phase 2b data readout for Rezpegaldesleukin (NKTR-358) in Alopecia areata. The expected timing is based on the latest available company guidance and may change.
REZOLVE-AA trial. 3/5/24- Ph2b initiated. 2/26/25- Completed target enrollment. 7/29/25- Fast Track designation. 9/18/25- Report results in December 2025. 11/06/25:- Company reiterated Fast Track designation for rezpegaldesleukin in severe-to-very-severe alopecia areata and confirmed expectation to report topline Ph2b data in December 2025. 12/15/25:- Company to release 36-week induction topline Ph2b REZOLVE-AA results and host webcast on December 16, 2025. 03/12/26:- December 2025 36-week REZOLVE-AA topline showed proof-of-concept; late-breaking AAD 2026 data and April extension readout planned. 03/20/26:- REZOLVE-AA Ph2b 36-week efficacy and safety results to be presented at AAD 2026 on March 28, 2026. 03/28/26:- REZOLVE-AA AAD 2026 late-breaking oral presentation delivered. Extension results remain upcoming. 04/20/26:- REZOLVE-AA NCT06340360 52-week blinded extension topline reported. Conference submission planned in 2026. 05/07/26:- End-of-Phase 2 FDA meeting in Q2 2026; 24-week REZOLVE-AA off-treatment data expected Q4 2026. 07/21/26:- Single registrational Ph3 alopecia areata trial planned Early 2027. 08/13/26:- Positive 52-week REZOLVE-AA results were reiterated. Data will be presented at EADV on October 1, 2026. Off-treatment data remain expected Q4 2026; Phase 3 is planned Early 2027.
Verification
Confirm timing and program details against the company announcement or filing.